Adelakun A, et al.
Cost‐effectiveness and public‐health impact of cabotegravir long‐acting injectable for HIV pre‐exposure prophylaxis in Canada
You are about to leave ViiVMedinfo.
By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.